FAQs About Glenmark’s Transition to Alivus Life Sciences

1. Why has Glenmark Life Sciences rebranded as Alivus Life Sciences?

The rebranding reflects the company’s desire to establish a distinct identity, separate from its parent company, Glenmark Pharmaceuticals. It aligns with its vision to expand its global footprint, drive innovation, and strengthen its position in the pharmaceutical industry.

2. What does the name “Alivus” mean?

“Alivus” signifies vitality, growth, and life—key attributes that represent the company’s mission to enhance global healthcare and improve lives through its pharmaceutical offerings.

3. Does the rebranding affect the company’s core business operations?

No, the core business operations, including the production of high-quality active pharmaceutical ingredients (APIs) and other products, remain unchanged. The rebranding is focused on creating a new identity while maintaining operational excellence.

4. Will the quality of products and services be impacted?

Absolutely not. Alivus Life Sciences is committed to upholding the same high standards of quality and reliability that customers have come to trust under the Glenmark Life Sciences brand.

5. What changes can stakeholders expect in the short term?

Stakeholders can expect updated branding across all communication channels, packaging, and documentation. However, the company’s dedication to its mission and values remains consistent.

6. Will there be any changes to existing contracts or agreements?

No, existing contracts and agreements remain valid. The rebranding does not impact the terms or conditions of any ongoing partnerships or collaborations.

7. How does this transition affect employees?

The rebranding offers employees an opportunity to be part of an exciting new chapter. It emphasizes growth, innovation, and a shared vision, fostering a sense of pride and purpose.

8. What does this mean for customers and clients?

For customers and clients, this transition means continuity in service and product quality. It also signals a renewed focus on meeting their needs with enhanced capabilities and innovative solutions.

9. Will the company’s leadership team change?

No, the leadership team remains the same. They will continue to guide the company’s strategic direction and ensure a seamless transition to the Alivus brand.

10. Is this rebranding part of a larger growth strategy?

Yes, the rebranding is a strategic move to position Alivus Life Sciences as a leading global player in the pharmaceutical industry, with plans to expand its market presence and capabilities.

11. How does this affect partnerships with suppliers?

Partnerships with suppliers remain unaffected. Alivus Life Sciences values its supplier relationships and is committed to maintaining strong collaborations.

12. Will there be any changes in the company’s product portfolio?

While the rebranding itself does not introduce immediate changes to the product portfolio, the company plans to expand its offerings and invest in R&D to meet evolving industry demands.

13. How will the rebranding affect global operations?

The rebranding is designed to strengthen the company’s global presence and enable it to compete more effectively in international markets. Customers and partners worldwide can expect improved accessibility and engagement.

14. How is Alivus Life Sciences communicating this change?

The company is using multiple channels, including press releases, direct communications, and updates on its website and social media platforms, to inform stakeholders about the rebranding.

15. What should customers or partners do if they have questions about the transition?

For any inquiries or concerns, customers and partners can reach out to the company’s support team or their designated point of contact. The company is committed to addressing all questions promptly.

The transition from Glenmark Life Sciences to Alivus Life Sciences marks an exciting new chapter in the company’s journey. By maintaining its commitment to quality and innovation, Alivus aims to build stronger relationships with its stakeholders and achieve new milestones in the pharmaceutical industry.